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in lung cancer treatment is variable according to several items:
the country where the treatment is performed, hospitalization,
administration and drug costs. METHODS: A total of 344 Lung
cancer patients were selected within the records of a private
hospital in Brazil. Of those, 69 patients that received pemetrexed
or docetaxel as second line chemo. The chemotherapy protocols
considered were: Pemetrexed 500mg/m2 every 3 weeks, Doc-
etaxel 75mg/m2 every three weeks, Docetaxel 35mg/m2 weekly (3
times per cycle) and Docetaxel 40mg/m2 weekly (3 times per
cycle). HRU frequency (hospitalization, clinical visits, comple-
mentary examinations, medication, transfusions) related to lung
cancer treatment was reviewed retrospectively from clinical
records. The costs were calculated in dolars (US$) following the
original records for each cycle. The values for neutropenia were
also calculated. RESULTS: Pemetrexed 500mg/m2 every three
weeks was used by 20.5% of the patients; Docetaxel 75 mg/m2
every three weeks by 17.1%; Docetaxel 35mg/m2 weekly (3 times
per cycle) by 8.1% and Docetaxel 40mg/m2 weekly (3 times
per cycle) by 1.1%.The cost of each cycle was U$6897.00 for
Pemetrexed 500mg/m2; US$3041.00 for Docetaxel 75mg/m2;
US$5919.00 for Docetaxel 35mg/m2 and US$6669.00 for Doc-
etaxel 40mg/m2. The costs of neutropenia and febrile neutrope-
nia episodes were respectively US$1310.00 and US$6000.00.
CONCLUSION: Besides the cost of the drug is a mean point in
health resources utilization we have to consider other variables to
have a clear picture of each chemotherapy scheme costs and were
the resources have been used. Since the chance of toxicity is
different for every kind of treatment, all the inputs to reach the
total cost of treatment are necessary.
PCN13
BUDGET IMPACT ANALYSIS OF SORAFENIB INTHE
TREATMENT OF HEPATOCELLULAR CARCINOMA
IN CANADA
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OBJECTIVE: To determine the ﬁnancial impact of sorafenib in
the treatment of hepatocellular carcinoma (HCC), the most
common form of liver cancer, from a Canadian provincial drug
plan perspective for 2008–2010. METHODS: A prevalence-
based approach was used to estimate the number of HCC
patients in Canada. Liver cancer prevalence from 2008–2010
was estimated using the GLOBOCAN 2002 database, supple-
mented with actual and projected Canadian liver cancer inci-
dence ﬁgures from 2003–2010, and survival rates for each stage
of HCC. Liver cancer ﬁgures were condensed to HCC ﬁgures as
~90% of liver cancers are HCC. HCC ﬁgures were then seg-
mented using the Barcelona Clinic Liver Cancer staging system
and diagnosis rates provided the clinical community. Age and
geographic distribution patterns, market share assumptions and
provincial drug plan coverage factors were then applied to the
HCC ﬁgures to determine the number of HCC patients eligible
for treatment with sorafenib and coverage from the province.
Drug costs including wholesale and pharmacy mark ups were
multiplied with the median treatment duration and patient
number to determine the ﬁnancial impact of sorafenib.
RESULTS: The prevalence of liver cancer in Canada in 2008 has
been estimated to be 1284 increasing to 1324 by 2009 and 1366
by 2010. Of these an estimated 206 HCC patients will be treated
with sorafenib in 2008, increasing to 321 in 2009 and 438 in
2010. The number of HCC patients treated with sorafenib that
are eligible to receive coverage through their provincial drug plan
are 154, 240 and 328 in 2008, 2009 and 2010 respectively. The
ﬁnancial impact of sorafenib to the provincial drug plans is $3.7
million in 2008, $7.1 million in 2009 and $9.7 million in 2010.
CONCLUSION: The ﬁnancial impact of sorafenib to the pro-
vincial drug plans will range from $3.7 million to $9.7 million
from 2008–2010.
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OBJECTIVE: We sought to systematically review economic
analyses (EAs) of HER2 testing and trastuzumab therapy in all
stages of breast cancer (BC) with speciﬁc attention to the meth-
odological quality, quantiﬁcation of uncertainty and incorpora-
tion of diagnostic test characteristics. METHODS: EAs of
trastuzumab in BC or HER2 diagnosis with either immunohis-
tochemistry or ﬂuorescence in situ hybridisation techniques were
considered. Biosis, Cochrane, CRD, EconLit, Embase, HEED,
Medline and PubMed databases were searched. The reference
lists of each retrieved article, relevant reviews, and abstracts of
the San Antonio Breast Cancer Symposium were hand-searched.
Citations were reviewed in duplicate and relevant articles were
qualitatively rated per Drummond. RESULTS: Twenty studies,
conference abstracts and health technology assessments were
selected for full review from among 641 citations as of December
2007 (reviewer agreement kappa = 0.85). Studies examined tras-
tuzumab in metastatic (7/20) or adjuvant (10/20) settings or had
a testing focus (4/20). HER2 diagnosis strategy and trastuzumab
treatment were evaluated jointly in only one study. Few decision
models were calibrated against epidemiological data (3/20).
Probabilistic sensitivity analysis was infrequently used to charac-
terise uncertainty (3/20) and decision uncertainty in the form of
cost-effectiveness acceptability curves was presented in a single
study. The overall reported quality of EAs was comparatively
poor. CONCLUSION: Testing and treatment were rarely exam-
ined in tandem, despite a 2004 EA addressing this very issue in
metastatic disease. Given the controversy around trastuzumab
funding in many jurisdictions, the need for adequate attention to
testing and uncertainty analysis is not met in the literature.
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OBJECTIVE: Two vaccines against cervical cancer are now
available. One reduces the burden of genital warts; with the other
the model estimates it may have better cross-protection against
oncogenic non-vaccine HPV-types. We aimed to understand the
extent to which cross-protection could have an equivalent cost
impact and the likelihood this would occur. METHODS: A
population model was developed in Excel(r) to evaluate the
expected annual health care cost of protecting cervical diseases
with vaccines against speciﬁc HPV-types. The type-speciﬁc
vaccine effect was assessed on the number of abnormal pap
smears, pre-cancer lesions, genital warts and cervical cancer cases
prevented. Vaccine effect was calculated by multiplying the pro-
portion of HPV-types per lesion, as reported in the literature, by
a range of vaccine efﬁcacy values. A health care perspective was
selected, with unit costs (2006 CDN$) for each intervention
obtained from ofﬁcial tariff data. No discounting was applied as
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results are reported over a one-year period after reaching steady-
state level of vaccination. Multiple probabilistic sensitivity analy-
sis was performed to estimate the distribution of the cost
difference between the two vaccines by running 5000 iterations
with @Risk(r) software in Excel(r) (normal distributions for
vaccine efﬁcacy, uniform distributions for HPV typing and costs).
RESULTS: Multiple probabilistic sensitivity analysis showed
an average annual cost difference of $9.3M (CDN) (95% CI:
-$10M, +$43M) in favor of cross-protection over genital warts
protection. Cross-protection provided additional cost saving
with an 86.3% probability. An efﬁcacy for additional cross
protection of around 12% would achieve cost neutrality. The
difference in cost was most sensitive to vaccine efﬁcacy of cross-
protection, the proportion of non-vaccine oncogenic HPV-types
in CIN1, and the unit cost of treating CIN1. CONCLUSION: A
vaccine with additional cross-protection of at least 12% is likely
to offset the costs associated with the protection against genital
warts in the Canadian health care system.
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COST DIVERSITY OF DRG BASED COLORECTAL CANCER
THERAPIES IN HUNGARY
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OBJECTIVE: In Hungary, costs of anti-cancer treatments are
covered by hospitals’ budget, and funds for therapy expenditures
provided from the National Health Fund Administration, based
on DRG accounts. The goal was to investigate the real cost of
treatments, and assess a comparison ofDRGbased remittance and
expenditures of therapies. METHODS: Cost analysis of CRC
chemotherapy-protocols has been conducted from the perspective
of Oncology Departments. Regimens of 5-ﬂuorouracil+/
-leukovorin, irinotecan, cetuximab, bevacizumab and oxali-
platin have been investigated, focusing on cost of medication,
hospitalisation and total expenditure of protocols. RESULTS:
Real expenditures of protocols were assessed. The range of drug
related costs were USD$18.20–3085.80 as expenditures of hospi-
tals. Total expenditures of chemotherapy-regimens have been
assessed and compared to allocation of remittances from the
National Health Fund Administration. The value of remittances
have been found between USD$405.70 and USD$2875.20,
depending on protocols. The gap analysis of drug expenditures
and remittances has resulted in a wide range of USD$-347 to
USD$1611. The ratio of drug related expenditures and total
remittance of hospitals showed diversity from 5% to 107%.
CONCLUSION: The analysis showed that ﬁxed DRG values had
not represented real expenditures of chemotherapies of CRC
treatment. Remittances should have been validated regularly.
Neither priority, nor incentive elements, have been found in
protocols containingmoleculeswith superior efﬁcacy or improved
safety. In general, Oncology Departments are motivated to use
protocols, containing generic compounds with low expenditures
and to achieve signiﬁcant savings in hospitals’ budget.
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A COST-EFFECTIVENESS ANALYSIS OF LAPATINIB AT A
TERTIARY CANCER CENTER
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OBJECTIVE: As new agents become available for the treatment
of diseases, there exists a need to evaluate the cost-effectiveness
of the agents. This study calculates the cost-per life-year saved
and the budget impact of lapatinib, a new dual tyrosine inhibi-
tor as part of the formulary evaluation process at a major ter-
tiary cancer center. METHODS: A decision analytical model
was developed to estimate the incremental cost-effectiveness of
lapatinib for advanced breast cancer. The model estimates the
incremental cost-effectiveness of two strategies: combination
therapy of lapatinib with capecitabine compared to capecitabine
alone. The outcome of interest was time to disease progression,
based on randomized clinical trials (RCTs). Direct medical costs
from the institutional perspective were utilized and were calcu-
lated for a one year time period. One-way and two-way sensi-
tivity analysis on the rate of disease progression for
monotherapy and combination therapy was conducted. In addi-
tion, a budget impact model was also calculated for the insti-
tution. RESULTS: Based on outcome estimates from RCTs and
the application of the institutional costs, the cost-per-life-year
saved for lapatinib for treatment of advanced breast cancer was
$108,300. One-way sensitivity analysis of the combination
response (0–50%) indicated that lapatinib’s cost-effectiveness
ratios ranged from $100,000 to $119,000 per life-year saved.
Two-way sensitivity analysis indicated that the majority of the
time monotherapy was more cost-effective. The lapatinib com-
bination was only considered cost-effective, if the response rate
of the monotherapy never exceeded 14.6%. The budget impact
model, which incorporated both on-label and off-label usage of
lapatinib, estimated that the institution will utilize about 10
million dollars worth of drugs annually, based on acquisition
costs. CONCLUSION: Lapatinib appears to have similar cost-
effectiveness in comparison with other targeted oncology agents.
Post evaluation economic analysis will be conducted to deter-
mine how closely the economic model predicted the utilization
of lipatinib at the institution.
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OBJECTIVE: Patients with chronic lymphocytic leukemia (CLL)
are often treated with prophylactic intravenous immunoglobulin
(IVIG) to reduce risk of infection, although increased survival has
not been demonstrated with use. The objective of this study was
to estimate direct medical costs of IVIG versus no prophylaxis
over 12 months. METHODS: Costs were estimated from the
government (Medicare) perspective when available, or calculated
from the literature in 2007 US dollars. Assuming a regimen of
400mg/kg every four weeks for one year, 12 administrations for
a 70kg patient was calculated using a reimbursement of $30 per
500mgs. Estimated resources costs were $24 per preparation and
$144 per administration. Infections were considered minor, mod-
erate, or severe and both costs and probabilities of infection were
extracted from previous studies. Risk of any infection with IVIG
use was 36% and with no prophylaxis, 56%. Reported infections
per year among patients with 1+ infection was 1.4 with IVIG use
and 2.25 infections with no prophylaxis. RESULTS: Under
the described model, the total cost per year of prophylactic
IVIG = $24,512 per patient. The weighted average cost per infec-
tion was $1688. The average weighted infection cost (AWIC)
of minor infections = $12; moderate, AWIC = $96; and severe,
AWIC = $2256. In comparison, total cost with no prophylaxis
was $4500 per patient year. The weighted average cost of one
infection with no prophylaxis = $2000. The AWIC of minor
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